99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Launched by JONSSON COMPREHENSIVE CANCER CENTER · Apr 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new method to help doctors find prostate cancer that may have spread to the lymph nodes during surgery. The treatment involves using a special imaging agent called 99mTc-PSMA-I&S, which is given to patients before their surgery. This agent helps doctors identify lymph nodes that express a specific protein related to prostate cancer, making it easier to detect cancer that might not be visible otherwise.

To be eligible for this trial, participants must be men diagnosed with prostate cancer, either newly diagnosed or recurrent, and show evidence of cancer in their lymph nodes based on a specific type of scan called a PET/CT. They should also be scheduled for a procedure to remove lymph nodes from the pelvis. Participants can expect to receive the imaging agent before their surgery and will help researchers understand how effective this method is in detecting cancerous lymph nodes. It’s important to note that men who have started treatment for prostate cancer or have nodal locations that are difficult to reach may not qualify for the study.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men with PCa (primary or recurrent disease)
• • Men who received a 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) for staging or restaging
• • Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET/CT
• • Men who are scheduled for pelvic LN dissection (PLND)
• • Men who can provide oral and written informed consent
• • Men who can comply with study procedures
• Exclusion Criteria:
• • Patients who started any PCa treatment between study enrollment and surgery
• • Technically inaccessible nodal location